Immunohistochemistry (IHC) Market

Immunohistochemistry (IHC) Market by Product (Antibodies, Reagents (Chromogenic Substrates), Kits), Application (Diagnostics (Cancer, Infectious), Research, Forensic), End User (Hospitals, Diagnostic Laboratories, Academic) - Global Forecast to 2025

Report Code: BT 4780 Jul, 2020, by marketsandmarkets.com

The global immunohistochemistry market is projected to reach USD 2.7 billion by 2025 from USD 1.9 billion in 2020, at a CAGR of 6.6% during the forecast period. The increasing incidence and prevalence of cancer, technological advancements in IHC, and the availability of reimbursement for IHC tests are the major factors driving the growth of this market.

Immunohistochemistry Market

COVID-19 impact on the global IHC market

Globally, the COVID-19 outbreak has impacted every aspect of the diagnostic industry, including IHC testing. In the last few months, the number of patient visits to hospitals has reduced significantly, despite emergency OPD and laboratory services being available in hospitals.

After commencing cancer surgeries or any other surgeries, surgeons run an IHC test/assay to decide the best treatment for patients. However, due to lockdowns in Q1 & Q2 2020 in many countries, the number of elective surgeries and diagnostic tests has significantly reduced. As a result, the number of IHC tests has reduced. This has significantly reduced the sales of IHC products in Q1 2020 and, to some extent, in Q2 2020.

Following are some of the government initiatives to delay screening or diagnostic tests for cancer:

  • In March 2020, the Welsh government and the Scottish government suspended screening programs for breast, cervical, and bowel cancer.
  • In the US, the Centers for Medicare & Medicaid Services classified screening as a low-priority service and suggested healthcare organizations to consider postponing screenings.
  • The interim Chief Medical Officer of Scotland reported that urgent referrals of patients with cancer by primary-care physicians had been reduced by over 70% by mid-April compared with the weekly average over the past three years.
  • Similar reductions have been reported in England. By assuming urgent cancer referrals have a conversion rate of 7%, Cancer Research UK has estimated that this reduction in referrals could mean around 2,000 fewer cancers are being diagnosed per week.

Immunohistochemistry Market Dynamics

Driver: Growing incidence and prevalence of cancer

Over the years, the prevalence of cancer has risen rapidly across the globe. According to GLOBOCAN, in 2018, the prevalence of cancer was 43.8 million globally (9.6 million cancer deaths were registered in the same year). The incidence of cancer was 18.1 million new cases in 2018, and this figure is expected to increase to 29.5 million by 2040. The increase in the incidence of cancer can be attributed to the growing geriatric as well as the total population.

Immunohistochemistry is most commonly used in the diagnosis and management of cancer. Some of the diagnostic uses of IHC include distinguishing invasive carcinoma from pseudo-invasive lesions, differentiating usual ductal hyperplasia (UDH) from atypical ductal hyperplasia (ADH/LG-DCIS), ruling out micro-invasion, identifying breast cancer histologic subtypes and molecular phenotypes, and confirming the breast as the primary site in metastatic carcinoma. The use of IHC in the management of metastatic melanoma with the help of PD-L1 IHC immune therapeutics in the recent past has revolutionized immuno-oncology. It is also used to predict therapeutic response in two important tumors, i.e., carcinoma of breast and prostate. Thus, the rapidly growing incidence and prevalence of cancer will propel the demand for immunohistochemistry products.

Restraint: High degree of consolidation

The global immunohistochemistry market is consolidated at the top, with the top three companies—F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US)—commanding a share of ~70-80% in 2019.

Patent expiry of antibodies is a major challenge in the immunohistochemistry market. Some of the primary antibodies manufactured and marketed by Roche Diagnostics (Switzerland) and Merck (Germany) are nearing patent expiration. As a result, the overall revenue and profitability of these market players is decreasing. Moreover, industry players are facing challenges such as rising price pressure from governments across the globe and reduced R&D output. To overcome these challenges, large market players are acquiring smaller and mid-sized market players that have innovative patented products. This provides a large financial and distribution platform for these products to increase their coverage into new markets globally.

To cater to the increasing demand for immunohistochemistry, major players are focusing on acquiring regional market players to enhance their distribution network and gain their existing customer base. This strategy has not only helped market players to gain additional revenues but also to sustain their position among changing market dynamics. The key players that adopted this strategy are Roche Diagnostics (Switzerland), Danaher Corporation (US), Agilent Technologies (US), Miltenyi Biotech (Germany), SLMP, LLC. (US), and Abcam plc (UK). As a result, it is difficult for new entrants in this market to compete with existing players and differentiate themselves with innovative product offerings. The major entry barriers for new entrants are consequently expected to restrict investments and, thus, the growth potential of this market.

Opportunity: Increasing demand for personalized medicine

Personalized medicine for non-small-cell lung cancer patients has proven to be extremely effective, and its use is expected to increase in the future. Immunohistochemistry techniques support this approach to treatment decision-making by performing the most complete and accurate histological subtyping of tumors possible (supported by predictive immunohistochemistry and the assessment of relevant biomarkers). Moreover, the increased availability of immunohistochemistry assays that detect mutant proteins (e.g., BRAF V600E and IDH1 R132H) provides a helpful replacement and/or adjunct for molecular testing. These techniques are highly reproducible, entail reasonable technical and interpretation complexity, and are available at relatively lesser costs, making them valuable novel tools in modern cancer care. The development of multiplex and mutation-specific immunohistochemistry assays represents important innovations, which provide improved utility in the context of personalized medicine and targeted therapy. The PD-L1 IHC assay is currently being used in late-stage nivolumab clinical studies for multiple indications, including non-small-cell lung cancer.

Similarly, tissue diagnostic reagents, test products, instrumentation, and other related products, which are widely used by both clinical and research laboratories, are an integral part of the development of personalized medicine. As a result, the growth of the tissue diagnostics market (this market is expected to grow from USD 3.4 billion in 2020 to USD 4.7 billion by 2023, at a CAGR of 6.5%, according to MarketsandMarkets Repository) is expected to provide opportunities for the growth of the IHC market (as IHC is a part of tissue diagnostics).

By product, the atibodies segment accounted for the largest share of the IHC  market in 2019.

Based on the product, the IHC market is segmented into antibodies, reagents, equipment, and kits. In 2019, the antibodies segment accounted for the largest share of the IHC market. The large share of this segment can be attributed to the mandatory use of antibodies in carrying out the immunohistochemistry diagnosis of various diseases (including cancer, infectious diseases, and other diseases) and the growing use of research antibodies for drug development.

By application, the diagnostic  segment accounted for the largest share of the IHC market in 2019.

Based on applicationthe IHC market is segmented into diagnostic, research, and forensic applications. Diagnostic applications accounted for the largest share of this market, owing to the increasing incidence & prevalence of cancer, growing burden of infectious diseases, and the favorable reimbursement scenario for IHC tests.

North America accounted for the largest share of the immunohistochemistryss market in 2019.

In 2019, North America accounted for the largest share of the IHC market. The growth in this regional market can be attributed to the presence of major players operating in the IHC market in the US, rising incidence of cancer and infectious diseases, and the increasing adoption of companion diagnostic assay kits.

Immunohistochemistry Market by Region

The global IHC market is dominated by a few globally established players such as F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US) Danaher Corporation (US), PHC Holding Corporation (Japan), Biocare Medical, LLC. (US), and Merck KGaA (Germany).

Scope of the report

Report Metric

Details

Market Size Available for Years

2018–2025

Base Year Considered

2019

Forecast Period

2020–2025

Forecast Units

Value (USD)

Segments Covered

Product, Application, End User, and Region

Geographies Covered

North America, Europe, APAC and the RoW

Companies Covered

The major market players include  F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, InC.. (US), Danaher (US), Bio SB, Inc (US), Becton, Dickinson and Company (US), Merck KGaA (Germany), PHC Holdings Corporation (Japan), and  Biocare Medical, LLC. (US).
(Total 25 companies)

The study categorizes the IHC market into the following segments and subsegments:

By Product

  • Antibodies
    • Primary Antibodies
    • Secondary Antibodies
  • Reagents
    • Histological Stains
    • Blocking Sera and Reagents
    • Chromogenic Substrates
    • Fixation Reagents
    •  Organic Solvents
    • Proteolytic Enzymes
    • Diluents
    • Other Reagents (stabilizers, controls, antigen retrieval reagents, and mounting reagents)
  • Equipment
    • Slide Staining Systems
    •   Tissue Processing Systems
    •    Slide Scanners
    •     Other Equipment (automated cover slippers, microtomes, paraffin dispensers, tissue microarray systems, and slide labelers)
  • Kits
    • Human IHC Kits
    • Animal IHC Kits

By Application

  • Diagnostics
    • Cancer
    • Infectious Diseases
    • Nephrological Diseases
    • Neurological Diseases
    • Autoimmune Diseases
    • Other Diseases (ophthalmic, dermatological, cardiac, and dental diseases as well as diabetes)
  • Research
    • Drug Developmet & Testing
    • Other Research
  • Forensic

By End User 

  • Hospitals & Diagnostic Laboratories
  • Academic & Research Institutes
  • Other End Users (include CROs, forensic labs, and pharma & biopharma companies)

Cell Expansion Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Rest of the World
    • Latin America
    • The Middle East and Africa

Recent Developments

  • In 2019, Roche launched the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody, the first and only in vitro diagnostic ROS1 immunohistochemistry (IHC) assay.
  • In 2019, Agilent received CE-IVD mark in Europe for its PD-L1 IHC 22C3 pharmDx assay for the identification of head and neck squamous cell carcinoma patients treated with KEYTRUDA.  
  • In 2019, PHC Holding acquired the Anatomical Pathology business (which deals with IHC products) of Thermo Fisher Scientific, Inc.
  • In 2018, Leica Biosystems launched a new PD-L1 antibody for use on its fully automated BOND IHC and ISH staining platform

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 35)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 40)
    2.1 RESEARCH DATA
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                 FIGURE 1 BREAKDOWN OF PRIMARIES: IMMUNOHISTOCHEMISTRY MARKET
           2.1.3 MARKET DATA ESTIMATION & TRIANGULATION
           2.1.4 DATA TRIANGULATION
                 FIGURE 2 DATA TRIANGULATION METHODOLOGY
    2.2 MARKET ESTIMATION METHODOLOGY
        FIGURE 3 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)
        FIGURE 4 IMMUNOHISTOCHEMISTRY MARKET SIZE (USD BILLION)
        FIGURE 5 IMMUNOHISTOCHEMISTRY MARKET: FINAL CAGR PROJECTIONS (2020−2025)
        FIGURE 6 IMMUNOHISTOCHEMISTRY MARKET: CAGR PROJECTIONS FROM THE ANALYSIS OF DEMAND-SIDE DRIVERS AND OPPORTUNITIES
    2.3 INDUSTRY INSIGHTS
    2.4 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY (Page No. - 46)
  FIGURE 7 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
  FIGURE 8 IMMUNOHISTOCHEMISTRY MARKET SHARE, BY APPLICATION, 2019
  FIGURE 9 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2020−2025
  FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE IMMUNOHISTOCHEMISTRY MARKET

4 PREMIUM INSIGHTS (Page No. - 49)
    4.1 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW
        FIGURE 11 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH
    4.2 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SHARE, BY END USER AND COUNTRY (2019)
        FIGURE 12 HOSPITALS & DIAGNOSTIC LABORATORIES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC IHC MARKET IN 2019
    4.3 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE
        FIGURE 13 PRIMARY ANTIBODIES SEGMENT WILL CONTINUE TO DOMINATE THE IHC ANTIBODIES MARKET IN THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 51)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
        FIGURE 14 IMMUNOHISTOCHEMISTRY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Growing incidence and prevalence of cancer
                            FIGURE 15 CANCER INCIDENCE, BY REGION AND TYPE OF CANCER, 2018
                    5.2.1.2 Technological advancements in IHC
                    5.2.1.3 Availability of reimbursements for IHC tests
                            TABLE 1 CPT CODES FOR IHC PROCEDURES
           5.2.2 RESTRAINTS
                    5.2.2.1 High degree of consolidation
                            TABLE 2 MAJOR ACQUISITIONS IN THE MARKET, 2015–2020
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increasing demand for personalized medicine
           5.2.4 CHALLENGES
                    5.2.4.1 Dearth of skilled professionals
                            TABLE 3 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018
                    5.2.4.2 Product failures and recalls
    5.3 IMPACT OF COVID-19 ON THE IMMUNOHISTOCHEMISTRY MARKET

6 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT (Page No. - 58)
    6.1 INTRODUCTION
        TABLE 4 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
    6.2 ANTIBODIES
        TABLE 5 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY REGION, 2018–2025 (USD MILLION)
        TABLE 6 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 7 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 8 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 9 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY REGION, 2018–2025 (USD MILLION)
        TABLE 10 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
           6.2.1 PRIMARY ANTIBODIES
                    6.2.1.1 Wide applications in diagnostics and research to support the demand for primary antibodies
                            TABLE 11 IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY REGION, 2018–2025 (USD MILLION)
                            TABLE 12 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 13 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 14 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 15 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY REGION, 2018–2025 (USD MILLION)
           6.2.2 SECONDARY ANTIBODIES
                    6.2.2.1 Signal amplification through conjugation and comparatively easy manufacturing to drive the market for secondary antibodies
                            TABLE 16 IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY REGION, 2018–2025 (USD MILLION)
                            TABLE 17 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 18 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 19 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 20 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY REGION, 2018–2025 (USD MILLION)
    6.3 REAGENTS
        TABLE 21 IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY REGION, 2018–2025 (USD MILLION)
        TABLE 22 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 23 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 24 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 25 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY REGION, 2018–2025 (USD MILLION)
        TABLE 26 IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2018–2025 (USD MILLION)
           6.3.1 HISTOLOGICAL STAINS
                    6.3.1.1 Developments in tumor detection and cancer disease progression studies to propel market growth
                            TABLE 27 IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY REGION, 2018–2025 (USD MILLION)
           6.3.2 BLOCKING SERA AND REAGENTS
                    6.3.2.1 Blocking sera and reagents prevent the nonspecific binding activity of antibodies
                            TABLE 28 IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY REGION, 2018–2025 (USD MILLION)
           6.3.3 CHROMOGENIC SUBSTRATES
                    6.3.3.1 Chromogenic substrates segment to register the highest growth during the forecast period
                            TABLE 29 IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY REGION, 2018–2025 (USD MILLION)
           6.3.4 FIXATION REAGENTS
                    6.3.4.1 North America is the largest market for fixation reagents
                            TABLE 30 IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY REGION, 2018–2025 (USD MILLION)
           6.3.5 ORGANIC SOLVENTS
                    6.3.5.1 Organic solvents prevent physical damage in specimens and improve clarity while visualizing tissue samples
                            TABLE 31 IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY REGION, 2018–2025 (USD MILLION)
           6.3.6 DILUENTS
                    6.3.6.1 Diluents are used in the preparation of antibody solutions
                            TABLE 32 IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY REGION, 2018–2025 (USD MILLION)
           6.3.7 PROTEOLYTIC ENZYMES
                    6.3.7.1 Proteolytic enzymes improve the accessibility of target antibodies
                            TABLE 33 IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY REGION, 2018–2025 (USD MILLION)
           6.3.8 OTHER REAGENTS
                    6.3.8.1 Other reagents include antigen retrieval solutions, stabilizers, controls, and mounting solutions.
                            TABLE 34 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY REGION, 2018–2025 (USD MILLION)
    6.4 EQUIPMENT
        TABLE 35 IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY REGION, 2018–2025 (USD MILLION)
        TABLE 36 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 37 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 38 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 39 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY REGION, 2018–2025 (USD MILLION)
        TABLE 40 IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION)
           6.4.1 SLIDE-STAINING SYSTEMS
                    6.4.1.1 Development of high-throughput staining systems to drive market growth
                            TABLE 41 IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2018–2025 (USD MILLION)
                            TABLE 42 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 43 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 44 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 45 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2018–2025 (USD MILLION)
           6.4.2 TISSUE PROCESSING SYSTEMS
                    6.4.2.1 Technological advancements and need for automation due to shortage of staff to drive market growth
                            TABLE 46 IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2018–2025 (USD MILLION)
                            TABLE 47 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 48 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 49 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 50 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2018–2025 (USD MILLION)
           6.4.3 SLIDE SCANNERS
                    6.4.3.1 Development of advanced multiplexed IHC scanners to drive market growth
                            TABLE 51 IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY REGION, 2018–2025 (USD MILLION)
                            TABLE 52 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 53 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 54 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 55 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY REGION, 2018–2025 (USD MILLION)
           6.4.4 OTHER EQUIPMENT
                 TABLE 56 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY REGION, 2018–2025 (USD MILLION)
                 TABLE 57 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 58 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 59 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 60 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY REGION, 2018–2025 (USD MILLION)
    6.5 KITS
        TABLE 61 IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY REGION, 2018–2025 (USD MILLION)
        TABLE 62 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 63 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 64 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 65 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY REGION, 2018–2025 (USD MILLION)
        TABLE 66 IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2018–2025 (USD MILLION)
           6.5.1 HUMAN IMMUNOHISTOCHEMISTRY KITS
                    6.5.1.1 Increasing focus on cancer research to fuel market growth
           6.5.2 ANIMAL IMMUNOHISTOCHEMISTRY KITS
                    6.5.2.1 Increasing preclinical drug testing to drive market growth

7 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION (Page No. - 86)
    7.1 INTRODUCTION
        TABLE 67 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
    7.2 DIAGNOSTIC APPLICATIONS
        TABLE 68 IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2018–2025 (USD MILLION)
        TABLE 69 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 70 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 71 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 72 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2018–2025 (USD MILLION)
        TABLE 73 IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2020–2025 (USD MILLION)
           7.2.1 CANCER
                    7.2.1.1 Growing use of IHC tests for cancer diagnostics to fuel the market growth
                            TABLE 74 IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY REGION, 2018–2025 (USD MILLION)
                            TABLE 75 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 76 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 77 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 78 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY REGION, 2018–2025 (USD MILLION)
           7.2.2 INFECTIOUS DISEASES
                    7.2.2.1 Growing prevalence of infectious diseases and rising awareness of early diagnosis to propel market growth
                            TABLE 79 IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2018–2025 (USD MILLION)
                            TABLE 80 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 81 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 82 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 83 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2018–2025 (USD MILLION)
           7.2.3 NEPHROLOGICAL DISEASES
                    7.2.3.1 Wide application of IHC in transplant rejection is expected to support market growth
                            TABLE 84 IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2018–2025 (USD MILLION)
                            TABLE 85 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 86 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 87 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 88 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2018–2025 (USD MILLION)
           7.2.4 AUTOIMMUNE DISEASES
                    7.2.4.1 Availability of numerous primary antibodies and rapid processing of results make IHC a favorable diagnostic approach
                            TABLE 89 IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2018–2025 (USD MILLION)
                            TABLE 90 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 91 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 92 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 93 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2018–2025 (USD MILLION)
           7.2.5 NEUROLOGICAL DISEASES
                    7.2.5.1 Increasing global burden of neurological diseases to propel market growth
                            TABLE 94 IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2018–2025 (USD MILLION)
                            TABLE 95 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 96 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 97 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2018–2025 (USD MILLION)
                            TABLE 98 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2018–2025 (USD MILLION)
           7.2.6 OTHER DISEASES
                 TABLE 99 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY REGION, 2018–2025 (USD MILLION)
                 TABLE 100 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 101 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 102 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 103 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY REGION, 2018–2025 (USD MILLION)
    7.3 RESEARCH APPLICATIONS
        TABLE 104 IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2018–2025 (USD MILLION)
        TABLE 105 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 106 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 107 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 108 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2018–2025 (USD MILLION)
           7.3.1 DRUG DEVELOPMENT & TESTING
                    7.3.1.1 Quantitative image analysis makes IHC techniques ideal for drug testing
           7.3.2 OTHER RESEARCH APPLICATIONS
                 TABLE 109 IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2018–2025 (USD MILLION)
    7.4 FORENSIC APPLICATIONS
        TABLE 110 IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY REGION, 2018–2025 (USD MILLION)
        TABLE 111 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 112 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 113 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 114 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY REGION, 2018–2025 (USD MILLION)

8 IMMUNOHISTOCHEMISTRY MARKET, BY END USER (Page No. - 107)
    8.1 INTRODUCTION
        TABLE 115 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2018–2025 (USD MILLION)
    8.2 HOSPITALS & DIAGNOSTIC LABORATORIES
           8.2.1 INCREASING INCIDENCE OF CANCER AND INFECTIOUS DISEASES TO INCREASE TESTING VOLUME IN CLINICAL LABORATORIES
                 TABLE 116 IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018–2025 (USD MILLION)
                 TABLE 117 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 118 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 119 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 120 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018–2025 (USD MILLION)
    8.3 ACADEMIC & RESEARCH INSTITUTES
           8.3.1 INCREASING USE OF IHC TESTS FOR DRUG DEVELOPMENT AND DISEASE DIAGNOSIS TO SUPPORT MARKET GROWTH
                 TABLE 121 IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018–2025 (USD MILLION)
                 TABLE 122 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 123 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 124 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION)
                 TABLE 125 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018–2025 (USD MILLION)
    8.4 OTHER END USERS
        TABLE 126 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY REGION, 2018–2025 (USD MILLION)
        TABLE 127 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 128 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 129 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 130 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY REGION, 2018–2025 (USD MILLION)

9 IMMUNOHISTOCHEMISTRY MARKET, BY REGION (Page No. - 115)
    9.1 INTRODUCTION
        TABLE 131 IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2018–2025 (USD MILLION)
    9.2 NORTH AMERICA
        FIGURE 16 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT
        TABLE 132 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 133 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
        TABLE 134 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 135 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 136 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 137 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
        TABLE 138 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION)
        TABLE 139 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.2.1 US
                    9.2.1.1 US is the largest country-level market for immunohistochemistry
                            TABLE 140 US: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 141 US: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 142 US: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 143 US: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                            TABLE 144 US: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION)
                            TABLE 145 US: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Increasing cancer cases in Canada to support market growth
                            TABLE 146 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 147 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 148 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 149 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                            TABLE 150 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION)
                            TABLE 151 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2018–2025 (USD MILLION)
    9.3 EUROPE
        TABLE 152 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
        TABLE 153 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
        TABLE 154 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 155 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 156 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 157 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
        TABLE 158 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION)
        TABLE 159 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Germany to dominate the European IHC market
                            TABLE 160 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 161 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 162 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 163 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                            TABLE 164 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION)
                            TABLE 165 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.3.2 FRANCE
                    9.3.2.1 Increasing use of IHC in cancer diagnosis and research to drive market growth
                            TABLE 166 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 167 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 168 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 169 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                            TABLE 170 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION)
                            TABLE 171 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.3.3 UK
                    9.3.3.1 Increasing number of cancer research studies to support market growth
                            TABLE 172 UK: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 173 UK: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 174 UK: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 175 UK: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                            TABLE 176 UK: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION)
                            TABLE 177 UK: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 High incidence of cancer to support market growth in Italy
                            TABLE 178 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 179 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 180 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 181 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                            TABLE 182 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION)
                            TABLE 183 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Increasing demand for personalized medicine will drive the demand for IHC tests to find potential biomarkers
                            TABLE 184 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 185 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 186 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 187 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                            TABLE 188 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION)
                            TABLE 189 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.3.6 REST OF EUROPE
                 TABLE 190 ROE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                 TABLE 191 ROE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
                 TABLE 192 ROE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION)
                 TABLE 193 ROE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                 TABLE 194 ROE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION)
                 TABLE 195 ROE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2018–2025 (USD MILLION)
    9.4 ASIA PACIFIC
        TABLE 196 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
        FIGURE 17 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT
        TABLE 197 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
        TABLE 198 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 199 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 200 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 201 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
        TABLE 202 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION)
        TABLE 203 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.4.1 JAPAN
                    9.4.1.1 Japan to dominate the Asia Pacific immunohistochemistry market
                            TABLE 204 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 205 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 206 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 207 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                            TABLE 208 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION)
                            TABLE 209 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.4.2 CHINA
                    9.4.2.1 China to register the highest growth during the forecast period
                            TABLE 210 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 211 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 212 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 213 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                            TABLE 214 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION)
                            TABLE 215 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 India is a key destination for high-end pathology and diagnostic services
                            TABLE 216 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 217 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 218 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 219 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                            TABLE 220 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION)
                            TABLE 221 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.4.4 REST OF ASIA PACIFIC
                 TABLE 222 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                 TABLE 223 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
                 TABLE 224 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION)
                 TABLE 225 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                 TABLE 226 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION)
                 TABLE 227 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2018–2025 (USD MILLION)
    9.5 REST OF THE WORLD
        TABLE 228 ROW: IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2018–2025 (USD MILLION)
        TABLE 229 ROW: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
        TABLE 230 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 231 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 232 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION)
        TABLE 233 ROW: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
        TABLE 234 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION)
        TABLE 235 ROW: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.5.1 LATIN AMERICA
                    9.5.1.1 Increasing incidence of cancer in Latin America is driving market growth
                            TABLE 236 LATAM: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 237 LATAM: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 238 LATAM: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 239 LATAM: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                            TABLE 240 LATAM: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION)
                            TABLE 241 LATAM: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.5.2 MIDDLE EAST AND AFRICA
                    9.5.2.1 Government initiatives focused on boosting healthcare infrastructure development to drive market growth
                            TABLE 242 MEA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
                            TABLE 243 MEA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 244 MEA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION)
                            TABLE 245 MEA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
                            TABLE 246 MEA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION)
                            TABLE 247 MEA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2018–2025 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 163)
     10.1 INTRODUCTION
     10.2 MARKET RANKING ANALYSIS
          FIGURE 18 COMPANY RANKING IN THE IMMUNOHISTOCHEMISTRY MARKET, 2019
     10.3 MARKET EVALUATION FRAMEWORK
          TABLE 248 MARKET EVALUATION FRAMEWORK: PRODUCT DEVELOPMENT & LAUNCH—THE MAJOR STRATEGY ADOPTED BY PLAYERS
     10.4 COMPETITIVE SCENARIO
             10.4.1 KEY PRODUCT LAUNCHES
             10.4.2 KEY COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS
             10.4.3 KEY EXPANSIONS
             10.4.4 KEY ACQUISITIONS

11 COMPANY EVALUATION MATRIX AND COMPANY PROFILES (Page No. - 167)
     11.1 OVERVIEW
     11.2 GLOBAL IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION MATRIX
             11.2.1 STARS
             11.2.2 EMERGING LEADERS
             11.2.3 PERVASIVE
             11.2.4 EMERGING COMPANIES
                    FIGURE 19 GLOBAL IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION MATRIX, 2019
     11.3 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View)*
             11.3.1 F. HOFFMANN-LA ROCHE AG
                    FIGURE 20 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2019)
             11.3.2 DANAHER CORPORATION
                    FIGURE 21 DANAHER CORPORATION: COMPANY SNAPSHOT (2019)
             11.3.3 AGILENT TECHNOLOGIES, INC.
                    FIGURE 22 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2019)
             11.3.4 MERCK KGAA
                    FIGURE 23 MERCK KGAA: COMPANY SNAPSHOT (2019)
             11.3.5 BIO-RAD LABORATORIES, INC.
                    FIGURE 24 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2019)
             11.3.6 PHC HOLDINGS CORPORATION
             11.3.7 BIO-TECHNE CORPORATION
                    FIGURE 25 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2019)
             11.3.8 ABCAM PLC
                    FIGURE 26 ABCAM COMPANY: COMPANY SNAPSHOT (2019)
             11.3.9 BECTON, DICKINSON AND COMPANY
                    FIGURE 27 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2019)
             11.3.10 PERKINELMER
                     FIGURE 28 PERKINELMER: COMPANY SNAPSHOT (2019)
             11.3.11 CELL SIGNALING TECHNOLOGY, INC.
             11.3.12 BIO SB, INC.
             11.3.13 MILTENYI BIOTEC
             11.3.14 CANDOR BIOSCIENCE GMBH
             11.3.15 SAKURA FINETEK JAPAN CO., LTD.
             11.3.16 EAGLEBIO
             11.3.17 BIOCARE MEDICAL, LLC
             11.3.18 ELABSCIENCE, INC.
             11.3.19 BIOGENEX
             11.3.20 DIAGNOSTIC BIOSYSTEMS

*Details on Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

12 APPENDIX (Page No. - 230)
     12.1 DISCUSSION GUIDE
     12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.3 AVAILABLE CUSTOMIZATIONS
     12.4 RELATED REPORTS
     12.5 AUTHOR DETAILS

This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global immunohistochemistry market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information and to assess market prospects. The size of the IHC market was estimated through various secondary research approaches and triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

The secondary sources referred to for this research study include publications from government sources, such as the WorldHealth Organization, Organization for Economic Co-operation and Development, GLOBOCAN, World Bank, World Cancer Research Fund International, Centers for Disease Control and Prevention, American Cancer Society, American Association for Clinical Chemistry, US Food and Drug Administration, European Commission, European Centre for Disease Prevention and Control, and European Diagnostic Manufacturers Association. Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations, among others. Secondary data was collected and analyzed to arrive at the overall size of the global immunohistochemistry market, which was validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global immunohistochemistry market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (such as personnel from the pharmaceutical and biopharmaceutical industry) and supply side (such as C-level and D-level executives, product managers, marketing and sales managers of key manufacturers, distributors, and channel partners, among others) across four major regions—North America, Europe, the Asia Pacific, and the Rest of the World. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

Immunohistochemistry Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Data Triangulation

After arriving at the overall market size, from the market size estimation process explained above, the IHC market was split into segments and subsegments. To complete the overall market engineering process and to arrive at the exact statistics for all segments and subsegments, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the IHC market

Report Objectives

  • To define, describe, segment, and forecast the immunohistochemistry market on the basis of product, application, end user, and region
  • To provide detailed information about the factors influencing market growth, such as drivers, restraints, opportunities, and challenges
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall immunohistochemistry market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, the Asia Pacific (APAC), and the Rest of the World (RoW)2
  • To profile the key players in the global immunohistochemistry market and comprehensively analyze their core competencies3 and market rankings
  • To track and analyze competitive developments, such as product launches, acquisitions, expansions, and partnerships in the immunohistochemistry market

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographical Analysis

  • Further breakdown of the European immunohistochemistry market into countries from the Rest of Europe.
  • Further breakdown of the Asia Pacific immunohistochemistry market into countries from the Rest of the APAC.
  • Further breakdown of the Rest of the World (RoW) immunohistochemistry market into Brazil, Mexico, Argentina, and the Rest of RoW countries.

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)
COVID-19

Get in-depth analysis of the COVID-19 impact on the Immunohistochemistry (IHC) Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Immunohistochemistry (IHC) Market

Request For Special Pricing
Report Code
BT 4780
Published ON
Jul, 2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Immunohistochemistry (IHC) Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2020 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home